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64Cu-DOTATATE PET for Neuroendocrine Tumors:
A Prospective Head-to-Head Comparison with
111In-DTPA-Octreotide in 112 Patients
Andreas Pfeifer1–3, Ulrich Knigge1,3,4, Tina Binderup1,3, Jann Mortensen1,3, Peter Oturai1,3, Annika Loft1,3,
Anne Kiil Berthelsen1,3, Seppo W. Langer3,5, Palle Rasmussen6, Dennis Elema6, Eric von Benzon1,3,
Liselotte Højgaard1,3, and Andreas Kjaer1,3
1Department of Clinical Physiology, Nuclear Medicine & PET and Cluster for Molecular Imaging, Rigshospitalet and University of
Copenhagen, Copenhagen, Denmark; 2Department of Nuclear Medicine, Helios-Klinikum Berlin-Buch, Berlin, Germany; 3ENETS
Center of Excellence for Neuroendocrine Tumors, Copenhagen, Denmark; 4Departments of Surgical Gastroenterology C and Medical
Endocrinology, Rigshospitalet, Copenhagen, Denmark; 5Department of Oncology, Rigshospitalet, Copenhagen, Denmark; and
6Hevesy Laboratory, DTU-Risø, Roskilde, Denmark
Neuroendocrine tumors (NETs) can be visualized using radio-
labeled somatostatin analogs. We have previously shown the
clinical potential of 64Cu-DOTATATE in a small first-in-human feasi-
bility study. The aim of the present study was, in a larger prospec-
tive design, to compare on a head-to-head basis the performance
of 64Cu-DOTATATE and 111In-diethylenetriaminepentaacetic acid
(DTPA)-octreotide (111In-DTPA-OC) as a basis for implementing
64Cu-DOTATATE as a routine. Methods: We prospectively enrolled
112 patients with pathologically confirmed NETs of gastroentero-
pancreatic or pulmonary origin. All patients underwent both PET/CT
with 64Cu-DOTATATE and SPECT/CT with 111In-DTPA-OC within
60 d. PET scans were acquired 1 h after injection of 202 MBq
(range, 183–232 MBq) of 64Cu-DOTATATE after a diagnostic con-
trast-enhanced CT scan. Patients were followed for 42–60 mo for
evaluation of discrepant imaging findings. The McNemar test was
used to compare the diagnostic performance. Results: Eighty-
seven patients were congruently PET- and SPECT-positive. No
SPECT-positive cases were PET-negative, whereas 10 false-negative
SPECT cases were identified using PET. The diagnostic sensitivity
and accuracy of 64Cu-DOTATATE (97% for both) were significantly
better than those of 111In-DTPA-OC (87% and 88%, respectively,
P 5 0.017). In 84 patients (75%), 64Cu-DOTATATE identified more
lesions than 111In-DTPA-OC and always at least as many. In total,
twice as many lesions were detected with 64Cu-DOTATATE than
with 111In-DTPA-OC. Moreover, in 40 of 112 cases (36%) lesions
were detected by 64Cu-DOTATATE in organs not identified as dis-
ease-involved by 111In-DTPA-OC. Conclusion: With these results,
we demonstrate that 64Cu-DOTATATE is far superior to 111In-DTPA-
OC in diagnostic performance in NET patients. Therefore, we do not
hesitate to recommend implementation of 64Cu-DOTATATE as a re-
placement for 111In-DTPA-OC.
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J Nucl Med 2015; 56:847–854
DOI: 10.2967/jnumed.115.156539
In well-differentiated neuroendocrine tumors (NETs), somato-
statin receptors are consistently overexpressed (1–3). This key
feature of NETs may be visualized using radiolabeled somatostatin
receptor ligands and SPECT or PET. Still, 111In-diethylenetriami-
nepentaacetic acid (DTPA)-octreotide is considered the standard
method according to current international guidelines (4,5). How-
ever, because of the better sensitivity, spatial resolution, and inher-
ently quantitative nature of PET, somatostatin receptor imaging
(SRI) with PET is increasingly used. Most common is the use of
the 68Ga-labeled somatostatin analogs, for example, 68Ga-DOTATATE
(6–9), 68Ga-DOTATOC (10–12), and 68Ga-DOTANOC (13). How-
ever, the high positron energy of 68Ga limits spatial resolution and
the short half-life of 68 min may be challenging logistically, because
production has to be aligned with patients and to be repeated several
times a day.
To overcome some of these challenges, we recently introduced
64Cu-DOTATATE, which has a long half-life of 12.7 h and can be
produced as a once-daily batch with a shelf life of more than 24 h
(14). These advantages of 64Cu-DOTATATE make it possible to
produce the tracer in a central location and distribute it to local
PET centers. The positron energy of 64Cu is also much lower than
that of 68Ga and therefore should translate into better spatial res-
olution (Table 1). In addition, by choosing the octreotate peptid for
this tracer, we have a better match for the commonly used therapy
ligand 177Lu-DOTATATE, enabling accurate diagnostic imaging
of the organs treated with 177Lu-DOTATATE.
The use of DOTA as a chelate has been challenged in several
studies (15,16). However, we demonstrated in our phase 1 study
sufficient in vivo stability of the 64Cu-DOTA complex to obtain
good-quality images (14), which we have also confirmed in pre-
clinical studies comparing DOTAwith other chelates (17–19). Data
from our first-in-human study of 14 patients demonstrated that
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imaging was feasible using an activity of 200 MBq, with a favorable
dosimetry of only 6.3 mSv (14). Compared with conventional SRI
using 111In-DTPA-octreotide (111In-DTPA-OC), additional lesions
were detected in 6 of 14 patients and 5 of these additional lesions
were found in organs not previously known as metastatic. In the
same study, we also found that PET could be performed between 1
and 24 h, and we selected the 1-h time point for routine use. Taken
together, data from our previous study allowed us to establish a stan-
dardized protocol for 64Cu-DOTATATE in NET.
The aim of the present study was therefore, on a larger scale, to
perform a prospective study comparing on a head-to-head basis in
112 NET patients the performance of 64Cu-DOTATATE and 111In-
DTPA-OC as a basis for implementing 64Cu-DOTATATE as a rou-
tine. To evaluate discrepant findings, patients were followed for
42–60 mo after the 2 scans were obtained.
MATERIALS AND METHODS
Patients and Inclusion Criteria
Eligible patients had histopathologically confirmed NETs of
gastroenteropancreatic or pulmonary origin of all grades (20). They
were enrolled in the study from November 2009 to May 2011, and
follow-up ended on November 15, 2014, for evaluation of discrepant
imaging findings. Accordingly, patients were followed for 42–60 mo.
Patients were offered study inclusion in the case of referral to con-
ventional SRI with 111In-DTPA-OC as part of their routine exami-
nations. 64Cu-DOTATATE PET and 111In-DTPA-OC SPECT were
performed within a maximum of 60 d (mean, 24 d) in a random order.
The study group consisted of 63 (56%) men and 49 (44%) women
with a mean age of 62 y (range, 30–84 y) (Table 2).
All patients gave written informed consent before inclusion. The
study was approved by the Regional Scientific Ethical Committee
(reference no. H-D-2008-045).
Radiotracer, Image Acquisition, and Reconstruction
Radiotracers. 64Cu-DOTATATE was produced in-house as previ-
ously described (14). The labeling efficiency was greater than 95%
(determined with radio–reversed-phase high-performance liquid chro-
matography), and the specific activity was 4.78 MBq/mmol. 111In-
DTPA-OC was purchased from Covidien and prepared in accordance
with the instructions of the manufacturer.
PET/CT. All patients were PET-scanned using a Biograph 64
TruePoint PET/CT scanner (Siemens Medical Solutions) with an axial
field of view of 216 mm and a transaxial field of view of 205 mm. Axial
and transaxial resolutions were 4.7 and 4.2 mm, respectively. Emission
scans were acquired 1 h after injection of 183–232 (mean, 202) MBq of
64Cu-DOTATATE, with an average of 44.6 mmol (40.2–50.9 mmol) of
octreotate administered per dose. Whole-body PET scans (skull to mid
thigh) were obtained in 3-dimensional mode, with an acquisition time of
3 min per bed position. PET data were reconstructed with the TrueX
(Siemens Medical Solutions) algorithm using 3 iterations and 21 subsets
and smoothed by gaussian filter (full width at half maximum, 2 mm). CT
data were used for attenuation correction. Before the PET scan, a diag-
nostic CT scan was obtained with 3-mm slice thickness, 120 kV, and
a quality reference of 225 mAs modulated by the Care Dose 4D automatic
exposure control system (Siemens Medical Solutions). Unless contra-
indicated, 75 mL of iodine-containing contrast agent were administered
using an automatic infusion system (Optiray 300; Covidien), with scan
delays of 60 s (flow rate, 1.5 mL/s), followed by an infusion of 100 mL
of NaCl (flow rate, 2.5 mL/s). Furthermore, patients had been asked to
drink 500 mL of water 25 min before image acquisition. PET and CT
images were fused and reviewed on a dedicated workstation.
SPECT/CT. Planar and tomographic images were acquired using
dual-head hybrid SPECT/CT cameras (Precedence 16-slice scanner
[Philips Healthcare]; VG Hawkeye [GE Healthcare]) after intravenous
administration of 181–268 (mean, 218) MBq of 111In-DTPA-OC.
Whole-body planar images (anterior and posterior, scan speed 5 cm/min,
512 · 1,024 matrix) were acquired at 24 h after injection and at 48 h
after injection if relevant (15-min static planar image [256 · 256
matrix] of the abdomen using a large-field-of-view medium-energy
collimator). During the same session, SPECT over the abdomen or
chest per indication (20 s/step, 128 angles, 128 · 128 matrix) was
performed. A low-dose CT (20 mA, 140 kV [Precedence] or 2.5 mA,
140 kV [Hawkeye]) was used as an anatomic guide and for attenuation
correction. Scatter correction was used, and SPECT and CT were
fused and reviewed on dedicated workstations (EBW [Philips Health-
care]; eNTEGRA [GE Healthcare]).
Visual Image Analysis and Activity Quantification
PET/CT and SPECT/CT were analyzed separately by 2 different
teams consisting of 2 experienced interpreters. The 2 teams were
masked to the images and readings of the other team. There had to
TABLE 1
Characteristics of Somatostatin Receptor Radiotracers
Characteristic 111In-DTPA-OC
68Ga-DOTATATE, 68Ga-DOTATOC,
68Ga-DOTANOC 64Cu-DOTATATE
Radionuclide from Cyclotron Generator Cyclotron
Physical half-life 2.8 d 68 min 12.7 h
Positron range
Mean in water — ≈3 mm ,1 mm
Maximum in water — ≈8 mm ≈3 mm
Radiation dosimetry* 5.6–11.1 mSv 2.0–5.1 mSv 5.7–6.9 mSv
Tracer labeling Locally (kit) Locally Centrally (or locally)
Shelf life of labeled compound† 6 h 3 h 24 h
Delayed imaging (.3 h) Possible Not possible Possible
*From Johnbeck et al. (36).
†111In-DTPA-OC: according to manufacturer’s instruction; 68Ga: limited by half-life of isotope to obtain 1 patient dose (new generator);
and 64Cu-DOTATATE: as approved by Danish Health and Medicines Authority.
848 THE JOURNAL OF NUCLEAR MEDICINE • Vol. 56 • No. 6 • June 2015
by Koebenhavns Universitetsbibliotek Nord on June 1, 2015. For personal use only. jnm.snmjournals.org Downloaded from 
be a clearly detectable lesion on the somatostatin receptor image to
be counted as SRI-positive in the case of lesion discovery on the
respective fused PET/CT or SPECT/CT images. CT data, masked
for both SPECT and PET, were additionally evaluated by an
experienced radiologist and used as a reference. The absolute
number of lesions per organ system was obtained with a numeric
limitation of 10 lesions per organ and 30 positive findings for
lymph nodes per patient.
Discrepant SRI findings—that is, foci that were recognized only on
1 of the 2 SRI methods—were classified as true-positive if they were
positive on the CT-only assessment performed masked to PET and
SPECT results but using the coregistered CT or were confirmed during
later follow-up on biopsies, by the other SRI modality, or on addi-
tional imaging (CT or ultrasonography).
Maximum standardized uptake values were calculated for the lesion
with highest tracer uptake in each organ obtained by drawing spheric
volumes of interest sufficiently large to encompass the whole lesion—
that is, including a rim of surrounding normal tissue.
Comparisons between the 2 methods were performed on the basis
of patients, organs, and lesions. Sensitivity, specificity, and accuracy
were calculated on a patient basis.
Statistical Analyses
The McNemar test for paired proportions with continuity correction
was applied to compare 64Cu-DOTATATE and 111In-DTPA-OC at the
patient level. The 95% confidence intervals for sensitivity, specificity,
accuracy, and predictive values were computed using the adjusted
Wald method. A sign test was used to explore differences in lesion
detection rates between the 2 SRI modalities. Two-sided P values of
less than 0.05 were considered statistically significant.
RESULTS
Patient-Based Comparison
One hundred twelve patients underwent 64Cu-DOTATATE PET,
111In-DTPA-OC SPECT, and contrast-enhanced diagnostic CT in
the inclusion period of 19 mo. In 100 of 112 NET patients, re-
sidual or recurrent disease was established on the basis of previous
clinical evaluation, CT, and SRI within the scope of this study and
prospective follow-up. Accordingly, 12 patients were negative for
disease and of these 12, 8 were expectedly negative as they were
newly operated on with removal of the known pathologic focus/
foci and referred for evaluation of possible residual disease.
Eighty-seven patients were congruently positive on both 64Cu-
DOTATATE PET and 111In-DTPA-OC SPECT scans. Ten patients
with proven residual or recurrent disease were identified only by
TABLE 2
Characteristics of Study Population (n 5 112)
Characteristic n
Sex
Male 63 (56%)
Female 49 (44%)
Mean age (y) 62 (range, 30–84)
Site of primary tumor
Lung carcinoid 9 (8%)
NET of unknown primary site origin 23 (21%)
Gastric NET 1 (1%)
Small intestinal NET 49 (44%)
Pancreatic NET 19 (17%)
NET originated from cecum/appendix 6 (5%)
NET originated from the rectum 2 (1.5%)
NET originated from extrahepatic
biliary tract
2 (1.5%)
NET originated from the esophagus 1 (1%)
Functional status
Nonfunctioning 72 (64%)
Functioning 40 (36%)
Carcinoid syndrome 35 (31%)
Gastrinoma 4 (3.6%)
Glucagonoma 1 (0.9%)
Grade (World Health Organization)*
Low-grade (G1) Ki-67, #2% 31 (28%)
Intermediate-grade (G2) Ki-67,
3%–20%
70 (62%)
High-grade (G3) Ki-67, .20% 9 (8%)
Ki-67 index not available 2 (2%)
Primary removed?
Yes 52 (46%)
No 60 (54%)
Previous treatment
Somatostatin analogs 35 (31%)
Surgery 56 (50%)
Chemotherapy 40 (36%)
Interferon α 47 (42%)
Radio frequency ablation
(liver metastases)
7 (6%)
External radiation therapy 2 (2%)
Hepatic artery chemoembolization 7 (6%)
Peptide receptor radionuclide therapy 18 (16%)
*Lung carcinoids all had mitotic counts # 10 and were accord-
ingly placed in G1 or G2 groups.
TABLE 3
Comparison of Diagnostic Performance of 64Cu-DOTATATE
and 111In-DTPA-OC
Parameter 64Cu-DOTATATE 111In-DTPA-octreotide
Sensitivity 97% (91%–99%)* 87% (79%–92%)*
Specificity 100% (96%–100%) 100% (96%–100%)
Accuracy 97% (92%–99%)* 88% (81%–93%)*
Positive
predictive
value†
100% (97%–100%) 100% (96%–100%)
Negative
predictive
value†
80% (54%–94%) 48% (30%–67%)
*P 5 0.017; 64Cu-DOTATATE vs. 111In-DTPA-OC (McNemar
test for paired proportions).
†At prevalence of disease of 89%.
Numbers in parentheses are 95% confidence intervals calcu-
lated using adjusted Wald method.
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64Cu-DOTATATE PET, leading to 97 true-positive 64Cu-DOTATATE
PET cases and 87 true-positive 111In-DTPA-OC SPECT cases.
111In-DTPA-OC SPECTwas false-negative in 13 patients, whereas
64Cu-DOTATATE PET was false-negative in 3 patients. Two of
these 3 matching false-negative cases comprised patients with
high-grade (G3) pancreatic NETs with liver metastases and Ki-
67 indices of 40% and 30%, respectively. The third patient had
been diagnosed with a bronchopulmonary carcinoid with a mitotic
count of 1 and liver metastases. No false-positive results for either
SRI modality were seen on a patient basis. Accordingly, sensitivity
for 64Cu-DOTATATE and 111In-DTPA-OC was 97% and 87%,
respectively. The comparison of diagnostic sensitivity, specificity,
accuracy, positive predictive value, and negative predictive value
and their 95% confidence intervals are shown in Table 3. The
McNemar test revealed a statistically different performance of
the modalities (P5 0.017), with 64Cu-DOTATATE having a higher
sensitivity and accuracy.
Five of the 10 patients with residual or recurrent NETs, which
were revealed only by 64Cu-DOTATATE PET, had liver metastases.
A typical case with discrepant PET and SPECT findings is
shown in Figure 1.
Another example in which PET compared with SPECT identified
3 additional organs with tumor involvement is shown in Figure 2.
Of 112 included patients, bone metastases were present in 38
cases (34%) of which PET detected 36 and CT the remaining 2.
All SPECT-positive cases were also PET-positive. In contrast, of
the 36 PET-positive cases, 13 cases (29%) were SPECT-negative.
Figure 3 shows a patient in whom multiple bone metastases were
FIGURE 1. Patient with gastric NET, which was not seen on 111In-
DTPA-OC SPECT (Precedence scanner) (A) but was clearly visible
(arrows) on 64Cu-DOTATATE PET (B). Likewise, CT did not reveal gas-
tric NET, but biopsy confirmed it to be a true-positive finding.
FIGURE 2. Multiple small liver metastases (.10), peritoneal solitary
tumor mass, and 3 lymph node metastases shown on 64Cu-DOTATATE
PET/CT in patient with pancreatic NET. No foci were detected by 111In-
DTPA-OC SPECT (Precedence scanner). All findings on PET were con-
firmed to be true-positive. (A) 111In-DTPA-OC planar images. (B) 64Cu-
DOTATATE maximum-intensity-projection image with arrows pointing
at liver and lymph node metastases. Insert is fused PET/CT of peritoneal
solitary tumor mass. (C) Axial CT and SPECT of liver. (D) Axial CT and
PET of liver revealing several small liver metastases.
FIGURE 3. Patient in whom PET identified more than 30 bone metas-
tases whereas SPECT (VG Hawkeye scanner) identified only 1, and no
bone lesions were visible on CT. During follow-up, multiple bone lesions
could be identified on subsequent CT and SPECT scans but not until 2 y
after lesions were found on the PET scan. (A) 111In-DTPA-OC from 2010.
(B) 64Cu-DOTATATE from 2010; arrow marks bone metastasis. (C) 111In-
DTPA-OC from 2012. (D) 64Cu-DOTATATE from 2012.
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revealed by 64Cu-DOTATATE in contrast to only 1 identified by
111In-DTPA-OC.
In another case, PET identified the primary tumor in the
terminal ileum and 1 abdominal lymph node metastasis whereas
SPECT identified only the abdominal lymph node metastasis. The
patient was subsequently operated on, and both foci were identified
and removed.
Organ-Based Comparison
An organ-based analysis yielded concordant findings in 72
(64%) patients—that is, that both 111In-DTPA octreotide and
64Cu-DOTATATE PET consistently showed no lesions or consis-
tently revealed at least 1 lesion for all organs/regions of the pa-
tient. In 40 of the 112 patients (36%), 64Cu-DOTATATE PET
detected lesions in additional organs/regions. There did not seem
to be a difference in performance between the 2 SPECT scanners
used, because there were 6 of the 21 patients (29%) scanned
using the VG Hawkeye with discrepant findings in comparison
to 34 of the 91 patients (37%) scanned using the Precedence
scanner with discrepant findings. In some patients, 2 or more
additional organ involvements were identified by PET, giving
a total of 58 additional organ involvements found on PET com-
pared with SPECT (Table 4). During the 42–60 mo of follow-up,
the additional organ involvements identified on PET were con-
firmed to be true-positive in 35 of the 40 patients. Details on
discrepant organ findings and how they were confirmed are given
in Tables 4 and 5.
The most common discrepant finding was lymph node metas-
tases. Thus, in 14 of the 40 discrepant cases, no lymph node
metastases were present on SPECT whereas PET identified up to
11 lymph node metastases. Only in 2 of the 40 patients did SPECT
identify more than 5 lymph node metastases whereas PET revealed
more than 5 lymph node metastases in 13 cases.
In 11 patients, no liver lesions were present on SPECT whereas
PET identified up to 20 liver metastases. In 3 of these 11 patients,
the liver metastases were also not evident on CT, but all 3 were
later confirmed to be true-positive lesions. In general for all 40
discrepant cases, PET identified at least as many and often more
lesions than both SPECT and CT.
All lesions detected on 111In-DTPA-OC SPECT were also
detected on 64Cu-DOTATATE PET. In 10 of the 40 cases, no
lesions were detected by SRS and in 5 of these patients the CT
scans were also negative.
Lesion-Based Comparison
In total, 1,213 lesions were detected by 64Cu-DOTATATE PET
in comparison to 603 lesions detected by 111In-DTPA-OC SPECT
(Table 6). Of the 112 patients, 21 (19%) were scanned on the VG
Hawkeye scanner, and in agreement with this, 123 (20%) of the
603 lesions detected by 111In-DTPA-OC were identified using the
VG Hawkeye scanner. In 28 patients (25%), PET and SPECT
identified the same number of lesions; in 52 patients (46%), PET
identified 1–9 more lesions than SPECT; and in 32 patients (29%),
PET identified 10 or more additional lesions than SPECT. Tables 5
and 6 provide further details.
The most frequent finding was liver metastases, for which 468
lesions were present on PET, compared with 320 on SPECT. The
clearest difference was the detection rate of bone metastases for
which 208 lesions were found on PET, compared with 90 on SPECT.
DISCUSSION
In this prospective cohort study of 112 patients, we compared
a new PET tracer, 64Cu-DOTATATE, with the SPECT-based gold
standard for imaging of somatostatin receptors in tumor lesions of
NET patients (21,22). We found that the PET-based tracer was far
superior to the current gold standard. With these results, we con-
clude that the 64Cu-DOTATATE PET tracer can safely be imple-
mented as a routine for diagnostic imaging of NET patients.
Recently, we developed and tested in a phase 1 study in 14
patients a new 64Cu-based tracer, 64Cu-DOTATATE, targeting so-
matostatin receptors (14). Although these initial results were most
promising, a larger study is needed before implementing the tracer
into clinical routine as replacement for 111In-DTPA-OC (Octreo-
scan; Covidien). In line with this, we prospectively studied a larger
series of 112 consecutive NET patients in a head-to-head compar-
ison study. In the present study, we found that twice as many foci
were identified. Still, whether 10 or 15 liver metastases are found
is not necessarily important additional information. However, also
when analyzing organ by organ, 58 additional organ systems were
found to be involved in 40 patients when 64Cu-DOTATATE was
used, compared with 111In-DTPA-OC, which could potentially be
TABLE 4
Organ-Based Analysis, Subgroup of 40 Patients with Discrepant Findings
Location of lesion
No. of additional PET
positive findings*
Confirmation by
Coregistered CT CT 111In-octreotide Biopsy Not confirmed
Lungs 5 4 1
Liver 11 8 2 1 0
Bones 13 3 3 1 6
Lymph nodes 14 9 1 1 3
Carcinomatosis 3 2 1
Pancreas 5 3 2 0
Others† 7 3 2 1 1
Total 58 30 12 3 1 12
*No. of PET foci does not equal no. of patients because some patients had more than 1 positive site.
†Others include 1 cerebral lesion, 1 peritoneal soft-tissue mass, 1 gastric lesion (primary), 1 chest wall lesion, 2 intestinal lesions
(1 primary tumor), and 1 ovary lesion.
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TABLE 5
Cases Showing Discrepant Results Between 64Cu-DOTATATE PET and 111In-Octreotide SPECT Scans
Identification no. 64Cu-DOTATATE PET 111In-DTPA-octreotide SPECT
Discrepant
organ
systems Confirmed?
1 CARC (1), OSS (.10), LN (.30), PUL* (6) CARC (1), OSS (1), LN (8) PUL Yes
2 MAM (.10), pSTM (1), LN (19),
HEP* (.10) 1 OSS* (1)
MAM (.10), pSTM (1), LN (1) HEP, OSS Yes
3 HEP (1), pSTM (1), OSS* (3), LN* (2) HEP (1), pSTM (1) OSS, LN Yes/OSS no
4† INT (1), HEP (.10), OSS (7), LN (6),
CARC* (1)
INT (1), HEP (.10), OSS (4),
LN (2)
CARC Yes
5† LN (1), PANC* (3), PUL* (4) LN (1) PANC, PUL Yes
6† HEP (1), pSTM (1), CARC (1), BRA* (1), OSS* (1) HEP (1), pSTM (1), CARC (1) BRA, OSS Yes/OSS no
7† HEP* (1), INT (1), OSS (.20), LN (13) INT (1), OSS (13), LN (2) HEP Yes
8 OSS* (1), LN* (4) None OSS, LN Yes/OSS no
9 HEP (.10), pSTM (1), LN* (6) HEP (.10), pSTM (1) LN Yes
10 HEP* (.10), pSTM* (1), LN* (3) None HEP, pSTM, LN Yes
11 INT (1), LN* (1) INT (1) LN No
12 HEP (.20), PANC (5), LN (4)* HEP (.10), PANC (1) LN Yes
13 HEP (2), LN* (2) HEP (1) LN Yes
14 STOMACH* (1), LN* (2) None Stomach, LN Yes/LN no
15 HEP (7), pSTM (1), CARC* (1) HEP (7), pSTM (1) CARC No
16 HEART/pericardium (4), pSTM (2), CARC (1),
OSS (.10), chest wall* (1), LN* (11)
HEART/pericardium (1),
pSTM (2), CARC (1), OSS (4)
Chest wall, LN Yes
17 Heart/pericardium (2), HEP* (3), INT (1),
pSTM (1), LN (.15)
Heart/pericardium (2), INT (1),
pSTM (1), LN (1)
HEP Yes
18 HEP* (.20), LN* (.10) None HEP, LN Yes
19† PANC (1), HEP* (1) PANC (1) HEP Yes
20 HEP (.10), PANC* (1), LN* (3) HEP (.10) PANC, LN Yes/LN no
21 INT* (1), LN (1) LN (1) INT Yes
22 HEP* (.10), LN (1) LN (1) HEP Yes
23 INT* (3), PANC* (1) INT (1) PANC Yes
24† HEP* (5), OSS* (1) None HEP, OSS Yes
25 PUL* (1), LN (1), OSS* (1) LN (1) PUL, OSS Yes/OSS no
26 HEP (2), pSTM (2), OSS* (10), LN (17) HEP (2), pSTM (2), LN (7) OSS Yes
27 CARC (2: hepatic, peritoneal), OSS* (5) CARC (2: hepatic, peritoneal) OSS Yes
28 INT (1), LN* (1) INT(1) LN Yes
29 PLEURA (4), HEP* (.10), PANC* (1),
OSS (.10), LN (1)
PLEURA (2), OSS (3), LN (1) HEP, PANC, Yes
30 HEP* (8) None HEP Yes
31 HEP* (3), PANC* (1), OSS* (3) None (neither primary) HEP, PANC, OSS Yes
32 PUL* (2), HEP (.10), INT* (1), pSTM (1),
OSS (6), LN* (1)
HEP (4), pSTM (1), OSS (1) PUL, INT, LN Yes/INT no
33 PUL* (1), OVAR (1), LN (17) OVAR (1), LN (3) PUL No
34 OVAR* (1) None OVAR Yes
35 INT (1), pSTM (1), CARC* (1) INT (1), pSTM (1) CARC Yes
36 PUL (1), HEP (.10), OSS* (2) PUL (1), HEP (.10) OSS Yes
37 PANC (1), HEP (.10), OSS* (1) PANC (1), HEP (4) OSS No
38 LN* (7) None LN Yes
39 HEP (.10), OSS* (2), LN (5) HEP (6), LN (3) OSS Yes
40 OSS* (2) None OSS Yes
*Not seen on 111In-DTPA octreotide.
†Patient scanned on VG Hawkeye scanner.
CARC 5 carcinomatosis; OSS 5 osseous; LN 5 lymphatic; PUL 5 pulmonary; MAM 5 mammary; pSTM 5 peritoneal soft-tissue mass;
HEP 5 hepatic; INT 5 intestinal; PANC 5 pancreatic; BRA 5 brain; OVAR 5 ovarian.
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of importance for the prognosis (23,24) and treatment selection
(25–28). Nevertheless, more foci found by PET are not necessarily
representative of true-positive foci. Therefore, we performed a long
follow-up to be able to evaluate whether foci were true-positive or
false-positive. With a follow-up of 42–60 mo, we found that 46
(79%) of the 58 discrepant findings could be evaluated as true-
positive on PET, and in no case were PET findings false-positive.
Accordingly, 64Cu-DOTATATE performs better than 111In-
DTPA-OC because it detects more regions truly involved in the
disease. When better performance is additionally accompanied by
a lower radiation dose of 6.3 mSv (14,29) and an easier workflow,
for example, a 1-d instead of 2-d procedure, we do not hesitate to
recommend implementing this technique in our routine as a re-
placement for 111In-DTPA-OC.
It may be argued that 68Ga-based tracers such as 68Ga-DOTATATE,
68Ga-DOTATOC, or 68Ga-DOTANOC would equally perform better
than 111In-DTPA-OC (30). Indeed, such comparative studies also
found more foci identified with 68Ga-based tracers than with
SPECT (27,31,32). These studies on average found 30%
(27,32,33) more foci using PET than SPECT. Compared with
our study in which we found a higher percentage of additional
lesions (50%), it seems we could have a better detection rate.
Moreover, 64Cu-DOTATATE found several lesions not detected
on CT scans, which is less commonly reported for the 68Ga-la-
beled tracers (32,34,35), which could easily be explained by the
better resolution obtained when using 64Cu than 68Ga due to the
4-fold-lower positron range of 64Cu. Moreover, in contrast to our
study with 64Cu, most of the 68Ga studies did not rigorously
perform a long-term follow-up to establish whether the addi-
tional foci were true-positive.
It could be asked how our tracer would perform in a head-to-
head comparison with 68Ga-based somatostatin receptor tracers.
Currently we do not know this, and because only a study also in-
cluding a long-term follow-up can answer which tracer is best, such
a study is not yet available. However, with 111In-DTPA-OC still
being the most commonly used tracer, in particular in the United
States, we find our current study timely and of clinical relevance.
CONCLUSION
With detection of twice as many lesions, identification of disease
involvement in organs not previously identified in one third of
enrolled patients, and a favorable dosimetry and workflow, we
have demonstrated that 64Cu-DOTATATE is far superior to 111In-
DTPA-OC. Accordingly, we do not hesitate to recommend imple-
mentation of this technique in our routine as a replacement for
111In-DTPA-OC.
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